Key statistics
On Thursday, Sagimet Biosciences Inc (0O2:BER) closed at 4.28, -32.60% below its 52-week high of 6.35, set on Mar 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.28 |
---|---|
High | 4.52 |
Low | 4.22 |
Bid | -- |
Offer | -- |
Previous close | 4.28 |
Average volume | 510.90 |
---|---|
Shares outstanding | 32.20m |
Free float | 26.35m |
P/E (TTM) | -- |
Market cap | 145.52m USD |
EPS (TTM) | -1.29 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:40 GMT.
More ▼
- Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
- Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
- Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
- Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
- Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
- Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
- Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
- Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
More ▼